redback spider antivenom

Redback spider antivenom is an equine-derived, purified immunoglobulin (F(ab')2 fragments) used for the treatment of systemic envenomation and severe local pain caused by the bite of the Australian redback spider (*Latrodectus hasselti*). Developed and manufactured by CSL (now Seqirus), the antivenom works by binding to and neutralizing the components of the spider's venom, primarily alpha-latrotoxin, which is responsible for the neurotoxic effects. Despite its long-standing use in Australia, the RAVE-II clinical trial (a randomized, placebo-controlled study) suggested that intravenous administration might not provide a clinically significant reduction in pain or systemic symptoms compared to placebo, leading to ongoing debate regarding its clinical utility.

Brand names

Redback Spider Antivenom

Other names

equine redback spider antivenom